Ozempic, other semaglutides linked to hair loss: Here's what to know
Popular medications for obesity and diabetes have been linked to an increased risk of hair loss, particularly for women.
TGA warning after counterfeit Ozempic pens detected at Australian border
Aussies have been warned to think before they jab, with more counterfeit Ozempic-labelled products seized at the border.
Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump
Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and ...
Novo Nordisk: Not As Bullish As Many
Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...
'I'm a doctor - I get asked these 7 questions about Mounjaro most often'
Here's everything you need to know about the new weight loss medication being rolled out by the NHS to treat obesity.
I went from size 24 to size 6 WITHOUT weight-loss injections through an unfashionable but tried-and-tested method that REALLY works: These women shar…
Ali couldn't buckle up her belt on an aeroplane seat without requesting an extension. Attempts at dieting had only led to ...
OneSource Pharma targets lion's share in generic GLP-1 market by FY27-28 as global demand surges
With blockbuster GLP-1 drugs such as Ozempic, Wegovy from Danish drug maker Novo Nordisk, and Mounjaro from American pharma ...
Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options
Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.
Warning as more counterfeit Ozempic products detected in Australia
Australians and health professionals are being warned to check the legitimacy of Ozempic products after a batch of illegal counterfeit injection pens was detected at the Australian border.The type of ...
‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS)
Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...
Applied Clinical Trials Online2h
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...